Optimising anti-TNF treatment using biosimilars Learning Zone

Welcome

Read time: 65 mins

Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.

This Learning Zone has been developed to provide practical advice and considerations on the use of biosimilars covering such topics as timely initiation, dose optimisation, the role of therapeutic drug monitoring, and cycling vs switching for anti-TNFs.

The importance of shared decision-making to improve adherence and persistence are also discussed, as well as how biosimilars are shaping anti-TNF exit strategies.

Click here to register now

This content has been developed independently of the sponsors who have had no editorial input into the content. Medthority received educational funding from the sponsor Biogen in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.